Please login to the form below

Not currently logged in
Email:
Password:

The Editors blog

An inside look at what’s happening within the pharma industry and across the PMGroup from the PMLiVE editorial team

Open season?

The EMA's decision to post minutes of CHMP meetings is another step forward for industry transparency

Just as pharma's frontrunners come into view with proposals to substantially advance the clinical trial data debate the EMA moves to address some of its own transparency issues.

The Agency has, for the first time, scraped away some opacity from its inner workings and begun publishing meeting minutes for its Committee for Medicinal Products for Human Use (CHMP). Given that the CHMP, as we well know, issues advice on which products to approve, the move could offer an intriguing glimpse into a previously closed world.

However, the first minutes published leave a little to be desired. Information considered “commercially confidential or sensitive” is “therefore not disclosed”, along with certain, unspecified aspects of on-going CHMP discussions. So whether we should have a positive opinion on the development or request a re-examination remains unclear. 

On a different note I'd like to end this month's comment by introducing the new look PME. We've given our little facelift a lot of thought and, though you'll still find the same vital combination of accessible intelligence within its pages, I hope the design changes will make it that much easier on the eye.

I'd welcome your feedback on the changes – or, for that matter, any aspect of PME – and you can contact me via email on dtyer@pmlive.com.

Article by
Dominic Tyer

editorial director of PMGroup

17th February 2014

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics